Several large recent clinical trials have established with reasonable certainty that chronic beta blocker therapy after acute myocardial infarction reduces two-year mortality by approximately 30%.1,2 However, given the projected 10% mortality during this time period, 100 patients must be treated to potentially save three lives. Identification of subgroups most (or least) likely to benefit from beta blockade would therefore be helpful. In a recently completed detailed analysis of the deaths in the Beta Blocker Heart Attack Trial (BHAT), we could find no major difference between propranolol and placebo groups in mechanism of death, incidence and type of acute or prodromal signs and symptoms, location of death, activity preceding death, or the percentage of deaths that were sudden or instantaneous.3 Thus, the protective effect of propranolol after myocardial infarction may be multifactorial.
Despite the almost 4000 patients participating in the trial, the total number of deaths is relatively small
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
* * SCHEDULED MAINTENANCE * *
Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.